Conduct CAPA Activities Appropriately, FDA Warns Manufacturers
This article was originally published in The Silver Sheet
CORRECTIONS, CORRECTIVE ACTIONS AND PREVENTIVE ACTIONS are not being applied correctly by manufacturers, FDA says. "Corrections are spot fixes for a particular product or issue [and] are followed by corrective actions, which are more systemic," says FDA/GMP expert Kim Trautman. Further, she often sees "so many things called 'preventive actions' that aren't preventive actions." A Global Harmonization Task Force draft guidance on the topic may clear up industry confusion. It details a four-part approach that companies can use when launching a CAPA system, including identifying quality data sources, analyzing data, conducting investigations and keeping top management informed. Device firms Becton Dickinson (BD) and AGA Medical also explain how they apply risk management principles to determine whether product problems should be elevated to their CAPA systems
You may also be interested in...
Capturing and analyzing product quality data appears to be a hiccup for many firms, but the problem can be addressed through the use of proper tools and effective monitoring of quality data sources, FDA officials explain. When quality data is added to a manufacturer’s CAPA system and properly analyzed, device problems may be discovered more quickly. Further, firms that inadequately define data sources in their procedures and mishandle information coming out of those sources will attract the notice of FDA investigators. “I would urge you to sit down with the investigator and show them your quality data elements and where the data is coming from, as well as how that information is analyzed,” said Phil Pontikos, FDA’s national expert on medical devices. “If you share those processes upfront, I think it will help expedite the inspection.”
GUIDANT HAD TOO MANY CAPA SYSTEMS and quality data databases that failed to link together. This problem helped lead to the now-defunct company's numerous recalls of implantable cardioverter defibrillators and pacemakers in 2005, an ex-employee says
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.